Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856225) titled 'Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer' on Sept. 28.
Study Type: Observational
Primary Sponsor: Fundación Santa Fe de Bogota
Condition:
Breast Neoplasms
Triple Negative Breast Neoplasms
HER2-Positive Breast Cancer
Hormone Receptor-Positive Breast Cancer
Intervention:
Drug: CDK4/6 Inhibitors
Drug: Anti-HER2 Therapy
Recruitment Status: Recruiting
Date of First Enrollment: December 1, 2025
Target Sample Size: 370
Countries of Recruitment:
Colombia
To know more, visit https://clinicaltrials.gov/study/NCT07856225
Published by HT Digital Content Services with permission fro...